GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Sapient Discovery Provides Insight on Lpath’s Cancer Drug Candidate

  • Sapient Discovery and Lpath reported the successful completion of a study to assess Lpath’s agent to treat cancer and various ocular diseases. The collaboration used Sapient Discovery's computational platform to understand the binding properties of Lpath's humanized sphingomab antibody to its target, sphingosine-1-phosphate (S1P).

    "Sapient Discovery's proprietary Genes-to-Leads technology created dynamic 3-D structural models of the binding of Sphingomab to S1P," explains Kal Ramnarayan Ph.D., president and CSO of Sapient Discovery, "This has provided valuable insights for the Lpath research team with significant efficiency and cost savings to Lpath."

    Lpath says it is the first to generate therapeutic Mabs against S1P, a bioactive lipid involved in angiogenesis and the progression of cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?